Our open innovation strategy is designed to promote change beyond GSK by sharing expertise, resources, intellectual property and know-how with external researchers and the scientific community.
Our previous focus was on diseases of the developing world, such as malaria, tuberculosis and parasitic infections and, we are now adapting open innovation models to apply to other areas of great medical need and scientific challenge including infectious, autoimmune disease, immuno-oncology and rare diseases.
Learn more about our open innovation strategy on our global site.
Our 30-year quest to develop a malaria vaccine
We’ve been fighting malaria on all fronts for the past 100 years - and are now on the verge of developing the first malaria vaccine - as well as signing a five-year partnership with Comic Relief to provide on-the-ground support in some of the worst affected areas.
Find out more
How we discover new medicines
Researching and developing a new medicine typically goes through several stages from laboratory to patient
How we discover new vaccines
Our vaccines R&D is focused on discovering prophylactic and therapeutic vaccines to protect people against infectious diseases, cancers and chronic disorders.
Consumer healthcare research
GSK products are built around science, and it is this innovation that is vital to our Consumer Healthcare business